Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data from its Phase 2 MIRA trial that suggested higher clinical responses and differentiation from competitors [4]. - Allegations have emerged that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising concerns about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, with claims centered around misleading statements regarding the efficacy of their drug candidate sonelokimab (SLK) compared to a competitor's product [1][3][4]. Group 1: Lawsuit Details - The lawsuit is titled Peters v. MoonLake Immunotherapeutics and is filed in the Southern District of New York [1]. - The class action seeks to represent purchasers or acquirers of MoonLake common stock during the class period [1][2]. - The lead plaintiff motions must be filed by December 15, 2025 [2]. Group 2: Company and Product Information - MoonLake is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [3]. - SLK is the company's sole drug candidate, primarily developed for treating hidradenitis suppurativa (HS) [3]. Group 3: Allegations Against MoonLake - The lawsuit claims that MoonLake made false statements regarding SLK's clinical benefits, asserting that SLK and BIMZELX share the same molecular targets and that SLK's unique structure would not provide superior efficacy [4]. - On September 28, 2025, MoonLake announced Phase 3 VELA program results indicating SLK did not demonstrate competitive efficacy against BIMZELX, leading to a nearly 90% drop in stock price [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 15, 2025 [3][5]. - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - MoonLake Immunotherapeutics, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, indicating potential concerns regarding the company's performance and transparency [1][3]. Group 1: Company Overview - MoonLake Immunotherapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Group 2: Legal Context - Investors have until December 15, 2025, to file a lead plaintiff motion in the class action lawsuit [1]. - The lawsuit suggests that SLK's commercial prospects hinge on its efficacy in treating HS, which is compared to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for the same condition [3]. Group 3: Investor Communication - Investors are encouraged to contact attorney Lesley F. Portnoy for legal rights discussions and to explore options for recovering losses [2][4].

Core Viewpoint - DJS Law Group is investigating Zions Bancorporation for potential violations of securities laws following a significant drop in stock price due to undisclosed loan issues [1][2]. Investigation Details - The investigation centers on whether Zions Bancorporation made misleading statements or failed to disclose critical information to investors [2]. - A Bloomberg article published on September 16, 2025, reported that Zions Bancorp's stock fell by 12% after the company revealed a $50 million charge-off related to a loan from its subsidiary, California Bank & Trust [2]. DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [3]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (NYSE: FLR) by Berger Montague on behalf of investors who acquired shares between February 18, 2025, and July 31, 2025, alleging that the company misled investors regarding its financial guidance and undisclosed risks associated with major infrastructure projects [1][3]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally. Its Urban Solutions segment is the largest revenue contributor among its three segments [2]. Lawsuit Details - The lawsuit claims that Fluor and certain executives failed to disclose rising costs related to significant projects, including the Gordie Howe, I-635/LBJ, and I-35 projects, which were impacted by subcontractor design errors, material price increases, and scheduling delays. Additionally, the company allegedly downplayed the adverse effects of reduced client capital spending and broader economic uncertainties [3]. Financial Guidance - In February 2025, Fluor projected an adjusted EPS for the full year 2025 in the range of $2.25 to $2.75 and EBITDA between $575 million and $675 million, which was reaffirmed in May 2025 [4]. Recent Performance - On August 1, 2025, Fluor reported disappointing second-quarter results, with non-GAAP EPS of $0.43, missing consensus estimates by 23%, and revenue of $3.98 billion, falling short by $570 million and down 5.9% year-over-year. The company significantly lowered its FY 2025 outlook, attributing the decline to project delays and reduced client awards. CEO James R. Breuer confirmed that the aforementioned projects were responsible for the poor performance. Following this announcement, Fluor's stock price dropped by $15.35, or 27.04%, closing at $41.42 [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) for the period between March 10, 2024, and September 29, 2025, due to alleged misleading statements and failure to disclose material facts regarding the company's products [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, defendants made false and/or misleading statements about the differences between Nanobodies and monoclonal antibodies, specifically regarding SLK and BIMZELX [5]. - Allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's Nanobody structure does not provide superior clinical benefits over traditional monoclonal antibodies [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [5]. Group 2: Participation Information - Investors who purchased MoonLake common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Sina Corporation by Berger Montague on behalf of investors who sold shares during the specified Class Period, alleging that the company engaged in a fraudulent scheme to undervalue its shares during a go-private transaction [1][3]. Group 1: Lawsuit Details - The lawsuit targets investors who sold Sina shares from October 13, 2020, to March 22, 2021, and they have until November 18, 2025, to seek lead plaintiff status [2]. - The allegations include that the defendants concealed the true value of Sina's investment in TuSimple, leading to a cash offer that significantly undervalued the company's shares [3][4]. Group 2: Company Background - Sina Corporation is a global digital media company based in Beijing, China, providing online platforms for news, social media, entertainment, and financial content [2]. - The lawsuit claims that senior executives were aware of the true value of the investment but chose to conceal it, resulting in shareholders receiving less than the actual worth of their shares during the transaction [4].

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and certain executives violated the Securities Exchange Act of 1934, impacting investors who purchased or acquired its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Allegations - The lawsuit claims that during the class period, MoonLake made false or misleading statements and failed to disclose critical information regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for HS [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide a clinical advantage over BIMZELX [4]. Stock Performance Impact - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, which indicated SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who suffered substantial losses and wish to serve as lead plaintiff in the class action lawsuit must file motions by December 15, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [7].